ROIVANT SCIENCES LTD (ROIV)
BMG762791017 - Common Stock
ROIV gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ROIV has an excellent financial health rating, but there are some minor concerns on its profitability. ROIV is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ROIV had negative earnings in the past year.
ROIV had a negative operating cash flow in the past year.
In multiple years ROIV reported negative net income over the last 5 years.
ROIV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ROIV (77.51%) is better than 99.65% of its industry peers.
Looking at the Return On Equity, with a value of 93.35%, ROIV belongs to the top of the industry, outperforming 99.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.51% | ||
| ROE | 93.35% | ||
| ROIC | N/A |
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ROIV has a Profit Margin of 6124.89%. This is amongst the best in the industry. ROIV outperforms 99.82% of its industry peers.
ROIV's Gross Margin of 89.14% is amongst the best of the industry. ROIV outperforms 92.04% of its industry peers.
In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 6124.89% | ||
| GM | 89.14% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ROIV has been increased compared to 1 year ago.
ROIV has a better debt/assets ratio than last year.
2.2 Solvency
ROIV has an Altman-Z score of 5.06. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ROIV (5.06) is better than 81.24% of its industry peers.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.06 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 10.43 indicates that ROIV has no problem at all paying its short term obligations.
ROIV has a Current ratio of 10.43. This is amongst the best in the industry. ROIV outperforms 82.48% of its industry peers.
ROIV has a Quick Ratio of 10.43. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
ROIV has a better Quick ratio (10.43) than 82.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.74% over the past year.
Looking at the last year, ROIV shows a very negative growth in Revenue. The Revenue has decreased by -23.86% in the last year.
The Revenue has been growing by 73.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.5%
Revenue 1Y (TTM)-23.86%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-21.13%
3.2 Future
ROIV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.63% yearly.
Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 61.23% on average per year.
EPS Next Y41.24%
EPS Next 2Y3.08%
EPS Next 3Y2.01%
EPS Next 5Y16.63%
Revenue Next Year-1.68%
Revenue Next 2Y-16.74%
Revenue Next 3Y5.57%
Revenue Next 5Y61.23%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.08%
EPS Next 3Y2.01%
5. Dividend
5.1 Amount
No dividends for ROIV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ROIVANT SCIENCES LTD
NASDAQ:ROIV (1/14/2025, 8:03:14 PM)
After market: 10.7206 -0.22 (-2.01%)10.94
+0.2 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners73.19%
Inst Owner ChangeN/A
Ins Owners7.49%
Ins Owner Change14.75%
Market Cap7.96B
Analysts85
Price Target17.41 (59.14%)
Short Float %8.58%
Short Ratio8.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)63.32%
Min EPS beat(2)-18.6%
Max EPS beat(2)145.25%
EPS beat(4)3
Avg EPS beat(4)43.33%
Min EPS beat(4)-18.6%
Max EPS beat(4)145.25%
EPS beat(8)4
Avg EPS beat(8)17.81%
EPS beat(12)6
Avg EPS beat(12)4.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.94%
Min Revenue beat(2)-41.71%
Max Revenue beat(2)71.59%
Revenue beat(4)2
Avg Revenue beat(4)8.34%
Min Revenue beat(4)-41.71%
Max Revenue beat(4)71.59%
Revenue beat(8)5
Avg Revenue beat(8)11.37%
Revenue beat(12)7
Avg Revenue beat(12)20.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.79%
PT rev (3m)0.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.25%
EPS NY rev (1m)1.62%
EPS NY rev (3m)6.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-57.54%
Revenue NY rev (1m)-12.05%
Revenue NY rev (3m)-24.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 101.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.55 | ||
| P/tB | 1.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.68
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.11
BVpS7.08
TBVpS7.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.51% | ||
| ROE | 93.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 6124.89% | ||
| GM | 89.14% | ||
| FCFM | N/A |
ROA(3y)-4.9%
ROA(5y)-0.13%
ROE(3y)-21.77%
ROE(5y)-11.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.41%
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 12.98% | ||
| Cap/Sales | 3.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 | ||
| Altman-Z | 5.06 |
F-Score6
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.5%
EPS Next Y41.24%
EPS Next 2Y3.08%
EPS Next 3Y2.01%
EPS Next 5Y16.63%
Revenue 1Y (TTM)-23.86%
Revenue growth 3Y73.73%
Revenue growth 5YN/A
Sales Q2Q%-21.13%
Revenue Next Year-1.68%
Revenue Next 2Y-16.74%
Revenue Next 3Y5.57%
Revenue Next 5Y61.23%
EBIT growth 1Y4.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-580.36%
EBIT Next 3Y-92.69%
EBIT Next 5YN/A
FCF growth 1Y11.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.22%
OCF growth 3YN/A
OCF growth 5YN/A